Ratio Therapeutics develops targeted radiopharmaceuticals using its proprietary Trillium™ targeting scaffold, which combines pharmacokinetic modulation with advanced chelation technology to enhance the delivery of therapeutic agents. The company addresses the need for effective treatments for solid tumors, including breast, pancreatic, lung, and colon cancers, by enabling precise imaging and therapeutic applications through its theranostic platform.
Funding
$94.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors, including breast, pancreatic, lung, and colon cancers, lack effective treatments due to limitations in targeted drug delivery and the inability to precisely image and treat cancerous cells. Current therapeutic approaches often suffer from off-target effects and insufficient drug accumulation within the tumor microenvironment.
Solution
Ratio Therapeutics develops targeted radiopharmaceuticals designed to improve the treatment of solid tumors. Their approach utilizes the Trillium™ targeting scaffold, a proprietary technology that combines pharmacokinetic modulation with advanced chelation. This scaffold enhances the delivery of therapeutic agents directly to the tumor site, enabling precise imaging and therapeutic applications. The company's theranostic platform facilitates both diagnostic imaging and targeted radiation therapy, potentially improving treatment efficacy and reducing off-target toxicity.
Target Audience
The primary target audience includes cancer patients with solid tumors, as well as oncologists and medical professionals seeking more effective and targeted treatment options.
Features
- Trillium™ targeting scaffold for enhanced drug delivery and pharmacokinetic modulation
- Advanced chelation technology for stable radioisotope binding
- Tunable platform accommodating both imaging and therapeutic radioisotopes (theranostic capabilities)
- Small molecule targeting agents designed to attack a broad array of cancer targets
- Capability for accelerated compound selection through small-scale imaging trials in patients
- Strong intellectual property positions across multiple platform technologies